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Abstract
A collection of 15 carbapenem-resistance Acinetobacter baumannii
clinical isolates was analysed on two tertiary hospitals in Mexico.
The OXA-51 was identified in all isolates, followed by OXA-239
and OXA-58; OXA-239 is described as a new OXA-23-like allele.
These carbapenemases were identified on four clonal groups,
distributed between two neighbouring hospitals. Acinetobacter
baumannii is poorly studied in Mexico; this situation urges the
implementation of strategies to prevent its dissemination.
Keywords: b-lactam antibiotics, carbapenem resistance, clonal
dissemination, multidrug resistance, nosocomial infection
Original Submission: 29 April 2014; Revised Submission: 10
July 2014; Accepted: 29 July 2014
Article published online: 22 September 2014
New Microbe and New Infect 2014; 2: 173–174
Corresponding author: J. Silva-Sanchez, Instituto Nacional de Salud
Publica, Av. Universidad #655, Col. Sta. Ma. Ahuacatitlan, C.P. 62100
Cuernavaca, Morelos, Mexico
E-mail: jsilva@insp.mx
Funding Information: This work was supported by grants
CB-2011-01-169867 from CONACyT (Mexican Council for Science
and Technology). a E. M. Tamayo-Legorreta and U. Garza-
Ramos contributed equally to the manuscript.
Dear Editor,
In the past two decades, Acinetobacter baumannii has become a
major pathogen, responsible for nosocomial infections. This
pathogen displays high carbapenem resistance due to the
production of carbapenemases, including the enzymes that
contribute to the resistance to carbapenems, carbapenem-
hydrolysing class D b-lactamases. Four groups have been
identified: blaOXA-51-like and three acquired ones
(blaOXA-23-like, blaOXA-24-like and blaOXA-58-like) [1],
however OXA-23 enzymes are found worldwide [2]. This
study describes the characteristics of carbapenem-resistant
A. baumannii clinical isolates in two tertiary-care hospitals in
Mexico City.
A collection of 15 non-duplicate A. baumannii clinical
isolates (one from each patient) was included. All of them
were imipenem-resistant and so were the cause of nosocomial
infections. They were collected between August and Decem-
ber 2010 at two hospitals belonging to the Centro Medico
Nacional Siglo-XII (CMN-XXI): Oncology (ten isolates) and
Cardiology (five isolates). The main isolation site corre-
sponded to tracheal aspirates (46.6%; 7/15). The bacterial
identification was carried out using API 20NE, and antimicro-
bial susceptibility was determined with the Phoenix system
(Becton Dickinson Company, Sparks, MD), using the com-
bined ID and AST NMIC/ID 104 panel for Gram-negative
bacilli. The MIC to imipenem, meropenem, tigecycline and
colistin were determined using the broth microdilution
method following the CLSI recommendations [3]. All isolates
were resistant to ampicillin, ceftazidime, ciprofloxacin, imip-
enem and meropenem, but they were susceptible to tigecy-
cline (0.25 lg/mL) and displayed a decreased susceptibility to
colistin (2–4 lg/mL) (Table 1). Clonal relatedness was deter-
mined by pulsed field gel electrophoresis and analysed
according to the criteria proposed by Tenover et al. 1995
[4], using the GELCOMPAR II software (Applied Maths, Sint-Mar-
tens-Latem, Belgium). Four clonal groups (A–D) were iden-
tified: Clone A included five clinical isolates from the
Cardiology hospital; the other minor clonal groups were
obtained from the Oncology hospital (Table 1). The multilo-
cus sequence typing (MLST) [5], was carried out in 8407
(clone A) and 8509 (clone B) isolates and the analysis
performed on the Acinetobacter MLST website, (http://pub-
mlst.org) showed that the sequence type (ST) was 758
(Table 1), corresponding to a new ST.
The phenotypic detection of metallo-b-lactamase produc-
tion was achieved by means of a disc approximation screening
test [3] and through a PCR assay for VIM, IMP, GIM, SPM and
NDM-1 genes, using generic primers as previously reported
[6,7]; all the results were negative. To detect the class D
carbapenemases (OXA-51, OXA-58, OXA-23 and OXA-24),
a PCR assay was performed using specific primers [7]. All
PCR-positive products were purified using a High Pure PCR
Product Purification Kit (Roche Applied Science, Indianapolis,
IN, USA); they were sequenced using the chain termination
method with a Big-Dye Terminator kit (Applied Biosystems,
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Foster City, CA, USA) and analysed on an ABIPRISMA 3100
(Applied Biosystems). The nucleotide sequences were com-
pared with the GenBank database by means of BLASTx
searches. The OXA-51 gene was identified in all isolates, and
in three and four isolates, respectively; OXA-58 and/or
OXA-23-like genes were detected. In the OXA-23-like gene,
three mutations were identified: S109L, D222N and P225S,
corresponding to a new allele, OXA-239 (GenBank
JQ837239) (http://www.lahey.org/Studies/) (Table 1). The
genetic context of the OXA-type genes was analysed by
PCR mapping, using ISAbaI and OXA-23 primers [8]. The
results showed that ISAbaI was not associated to the OXA-51
gene, whereas the ISAbaI sequence is flanking the OXA-239
gene, suggesting that its expression could be driven by the
promoter present in this insertion sequence, as previously
reported [9].
A new OXA-235 allele was described recently in one
A. baumannii clinical isolate in Mexico [10], this study described
another new OXA-23-like allele, OXA-239 gene in A. bau-
mannii ST758 clinical isolates with different clonal origin from
two tertiary-care hospitals from the same hospital complex in
Mexico City. Acinetobacter baumannii has been poorly studied
in Mexico; however, these studies show OXA enzyme
diversification, highlighting the emergence of the new
OXA-239 and for this and other reasons it is necessary to
implement strategies to identify these kinds of isolates and
prevent their dissemination.
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TABLE 1. Characteristics of carbapenem-resistant Acinetobacter baumannii clinical isolates
Strain Hospital PFGE MLST (ST) OXA-type IMP MEM TIG CL
8402 1 A ND 51 32 16 <0.125 4
8404 1 A ND 58, 51 32 16 <0.125 4
8400 1 A ND 51 8 16 0.25 4
8407 1 A 758 239, 58, 51 32 32 0.5 4
8406 1 A ND 51 32 32 0.5 4
8511 2 B ND 239, 58, 51 32 8 1 4
8513 2 B ND 51 32 8 1 2
8509 2 B 758 239, 51 32 8 1 4
8510 2 B ND 239, 51 32 8 1 4
8508 2 B ND 51 32 8 1 2
8506 2 C ND 51 32 8 1 2
8516 2 C ND 51 32 16 0.5 2
8517 2 C ND 51 32 16 1 2
8514 2 D ND 51 32 8 1 2
8515 2 D ND 51 32 8 1 4
Abbreviations: CL, colistin; IMP, imipenem; MEM, meropenem; MLST, The MultiLocus Sequence Typing; ND, not determined; PFGE, pulsed field gel electrophoresis; ST, sequence
type; TIG, tigecycline.
Hospitals: 1, Cardiology; 2, Oncology from Centro Medico Nacional Siglo-XII (CMN-XXI) in Mexico City.
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